Richard Hoffman is a partner in Goodwin’s Life Sciences group. Mr. Hoffman is a lawyer, consultant and entrepreneur in the life sciences industry, with extensive experience in establishing new companies, negotiating and closing venture capital financings, in-licensing technologies, and developing and implementing corporate and business development strategies. He also has a successful track record in structuring, negotiating, and documenting strategic deals with both public and private companies. He joined the firm in 2016.

Mr. Hoffman was formerly a partner with WilmerHale. He has previously worked in the biotech industry, serving as a legal advisor and business consultant to numerous biotech companies. As principal at R.A. Hoffman Consulting, he provided entrepreneurs and early-stage biotechnology, medical device and healthcare information companies with advice on corporate and business development strategies and tactics.

Prior to his consulting work, Mr. Hoffman served as Vice President of Finance and Business Development at Hybridon, Inc. (now a public company, Idera Pharmaceuticals), and later served in a similar capacity at biotech company Avitech, Inc.

Areas of Practice
Domaines D’Expertise





Mr. Hoffman’s practice is focused on privately held and publicly traded emerging growth companies with a strong emphasis on companies across the spectrum of the life sciences industry, including biotechnology, medical devices, diagnostics and healthcare information technology. He often serves as general counsel to his clients, closely advising management teams and boards of directors on a wide variety of matters throughout the company’s life cycle, including company formation, private equity financings, public offerings, mergers and acquisitions, strategic collaborations, commercial transactions, corporate governance and general corporate matters. Mr. Hoffman also regularly represents leading venture capital firms focused on the life sciences industry in connection with their portfolio company investments and company-initiation activities.

His recent client representations include work with:

  • Pairwise Plants in its initiation, $25 million Series A financing and R&D collaboration with Monsanto.
  • Deerfield Management as lead investor in the approximately $50 million Series A financing of Sollis Therapeutics.
  • Cullinan Oncology in its collaboration with MAB Discovery and the establishment of Cullinan Wittelsbach.
  • Arrys Therapeutics in its license of EP4 antagonists from AskAt Inc.
  • Innovative Targeting Solutions in its research collaborations with Sanofi and Janssen.
  • Nuvelution in its collaborative partnership with Teva to develop AUSTEDO® (deutetrabenazine).
  • Harvard in its license to Beam Therapeutics of a suite of revolutionary DNA base editing technologies for treating human disease.
  • Kyn Therapeutics in its $49 million Series A financing.
  • Deciphera in its approximately $130 million IPO.
  • Ablexis in its licenses with Five Prime Therapeutics, Janssen and Tri-Institutional Therapeutics Discovery Institute.
  • Deerfield Management as lead investor in the approximately $84 million Series B financing of Homology Medicines.
  • Goldfinch Bio in its collaborations with Icahn School of Medicine at Mount Sinai, Vanderbilt University, and NEPTUNE.
  • TARA Biosystems in its Series A financing.
  • Cydan in its option and in-license agreements, including those associated with Imara and Vtesse.
  • Syntimmune in its series preferred financings, including its $50 million Series B financing.
  • Deerfield Management as lead investor in the approximately $45 million B financing of Graybug Vision.
  • Deerfield Management as lead investor in the approximately $34 million B financing of Lumos Pharma.
  • Harvard in its license to Merck a group of small molecule drug compounds for the treatment of blood cancers, such as AML.
  • TriNetX in its initiation and subsequent series preferred financings.
  • Neon Therapeutics in its foundational in-licenses from the Broad Institute, Dana Farber Cancer Center and Massachusetts General Hospital.
  • Editas in its in-license from Massachusetts General Hospital.
  • ConforMIS in its approximately $140 million IPO.
  • Fedora Pharmaceuticals in its $750 million deal for ex-Japan rights to a novel beta-lactamase inhibitor.
  • Editas in its foundational in-licenses from the Broad Institute, Harvard University and Massachusetts Institute of Technology.
  • Eleven Biotherapeutics in its approximately $50 million IPO.
  • Ophthotech in its approximately $170 million IPO.
  • Ablexis in the structuring and negotiation of its novel consortium model of initial licenses to five of the top 15 pharmaceutical companies.

In The News









Columbia Law School
The Wharton School at the University of Pennsylvania
B.A., Biochemical Sciences
Harvard College
(magna cum laude)



District of Columbia
Get In Touch
Get in Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.


Search Other Lawyers
Recherche par Pratique